Skip to main content

Table 3 Adverse effects and liver function abnormality tests of the 84 virologically suppressed HIV-infected patients entered in this study

From: Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

a Comparison of adverse effects between NVP-XR and NVP-IR
  All N = 84 NVP-XR N = 35 NVP-IR N = 49 P
Skin rash, n (%) 1 (1.2) 1 (2.9) 0 (0.0) 0.42
Gastrointestinal disorders, n (%) 2 (2.4) 1 (2.9) 1 (2.0) 1.0
Tablet remnants in stools, n (%) 1 (2.4) 1 (2.9) 0 (0.0) 0.42
b Comparison of liver function abnormalities between NVP-XR and NVP-IR
  NVP-XR 400 mg qd (N = 35) NVP-IR 200 mg bid (N = 49) P
AST elevation, n (%) 6 (17.1) 12 (24.5) 0.42
  Grade I Grade II Grade III Grade IV Grade I Grade II Grade III Grade IV  
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
5 (14.3) 0 (0) 0 (0) 1 (2.9) 10 (22.4) 1 (2.0) 1 (2.0) 0 (0) 0.28
ALT elevation, n (%) 9 (25.7) 16 (32.7) 0.49
  Grade I Grade II Grade III Grade IV Grade I Grade II Grade III Grade IV  
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)  
8 (22.9) 0 (0) 0 (0) 1 (2.9) 13 (28.6) 2 (4.1) 1 (2.0) 0 (0)  
Bilirubin, n (%) 1 (2.9) 0 (0) 0.42
  Grade I Grade II Grade III Grade IV Grade I Grade II Grade III Grade IV  
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)  
1 (2.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)  
  1. AST aspartate aminotransferase, ALT alanine aminotransferase
  2. (a) Comparison of adverse effects between NVP-XR (n = 35) and NVP-IR (n = 49). (b) Comparison of liver function abnormalities between NVP-XR (n = 35) and NVP-IR (n = 49)